SCHEMBL8010277

SCHEMBL8010277

C=CCOC1CCCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.49
ALDH1A1 P00352 1/20 0.49
MAPT P10636 1/20 0.49
KMT2A Q03164 1/20 0.49
PRMT5 O14744 2/20 0.48
WDR77 Q9BQA1 2/20 0.48
HPGD P15428 1/20 0.44
NR1H2 P55055 1/20 0.42
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
PDE4B Q07343 1/20 0.39
EPHX1 P07099 1/20 0.39
GLS O94925 1/20 0.39
USP30 Q70CQ3 2/20 0.38
CHEK2 O96017 1/20 0.38
PIK3CD O00329 2/20 0.38
PREP P48147 1/20 0.38
ACKR3 P25106 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20477490 1.00 MEN1 (0.49) MEN1ALDH1A1MAPTKMT2APRMT5
SCHEMBL31618749 0.96 HPGD (0.46) MEN1ALDH1A1MAPTKMT2APRMT5
SCHEMBL31618562 0.96 HPGD (0.46) MEN1ALDH1A1MAPTKMT2APRMT5
SCHEMBL18689925 0.92 PRMT5 (0.46) MEN1ALDH1A1MAPTKMT2APRMT5
SCHEMBL31279449 0.92 PRMT5 (0.46) MEN1ALDH1A1MAPTKMT2APRMT5
SCHEMBL27406298 0.88 MEN1 (0.50) MEN1ALDH1A1MAPTKMT2APRMT5
SCHEMBL20128951 0.86 NR1H2 (0.51) MEN1ALDH1A1MAPTKMT2APRMT5
SCHEMBL5664877 0.83 ALDH1A1 (0.53) MEN1ALDH1A1MAPTKMT2APRMT5
SCHEMBL5664868 0.83 ALDH1A1 (0.53) MEN1ALDH1A1MAPTKMT2APRMT5
SCHEMBL1733959 0.83 HPGD (0.48) MAPTPRMT5WDR77HPGDNR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025081019-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS, INC. (US) 2025-04-17 WO disclosed
CN-108137541-B Pyridone dicarboxamides for use as bromodomain inhibitors 葛兰素史克知识产权第二有限公司 2021-07-06 CN disclosed
US-10370356-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2019-08-06 US disclosed
US-10370356-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2019-08-06 US disclosed
US-20180282301-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2018-10-04 US disclosed
EP-2268285-B1 THERAPEUTIC COMPOUNDS MERCK SHARP & DOHME (US) 2018-06-27 EP disclosed
US-9738661-B2 HCV NS3 protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-08-22 US disclosed
US-9738661-B2 HCV NS3 protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-08-22 US disclosed
WO-2017050714-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-03-30 WO disclosed
US-20150266897-A1 HCV NS3 Protease Inhibitors MSD ITALIA S.R.L. (IT) 2015-09-24 US disclosed
US-20150266897-A1 HCV NS3 Protease Inhibitors MSD ITALIA S.R.L. (IT) 2015-09-24 US disclosed
US-20110002884-A1 THERAPEUTIC COMPOUNDS MERCK SHARP & DOHME LLC 2011-01-06 US disclosed
US-20110002884-A1 THERAPEUTIC COMPOUNDS MERCK SHARP & DOHME LLC 2011-01-06 US disclosed
US-20100099695-A1 HCV NS3 Protease Inhibitors MSD ITALIA S.R.L. (IT) 2010-04-22 US disclosed
US-20100099695-A1 HCV NS3 Protease Inhibitors MSD ITALIA S.R.L. (IT) 2010-04-22 US disclosed
WO-2009108507-A1 THERAPEUTIC COMPOUNDS MERCK & CO., INC. (US) 2009-09-03 WO disclosed
WO-2008057209-A1 HCV NS3 PROTEASE INHIBITORS MERCK & CO., INC. (US) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10370356-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors BRD4, BRD3, BRDT MEN1 2738/4885ALDH1A1 1362/4885MAPT 157/4885
US-20100099695-A1 HCV NS3 Protease Inhibitors HAVCR2, GTF3C3, CTSC MEN1 4761/4885ALDH1A1 1199/4885MAPT 4330/4885
US-20150266897-A1 HCV NS3 Protease Inhibitors HAVCR2, GTF3C3, CTSC MEN1 4761/4885ALDH1A1 1199/4885MAPT 4330/4885
US-20110002884-A1 THERAPEUTIC COMPOUNDS RRP1B, ZC3HAV1, RNASE1 MEN1 3427/4885ALDH1A1 1039/4885MAPT 4169/4885
US-20180282301-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRDT MEN1 2738/4885ALDH1A1 1362/4885MAPT 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.